tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ADVM Stock Latest News

Positive Outlook for Adverum Biotechnologies: Buy Rating Based on Promising ixo-vec Therapy and Strategic Financing Plans
RatingsPositive Outlook for Adverum Biotechnologies: Buy Rating Based on Promising ixo-vec Therapy and Strategic Financing Plans
5d ago
ADVM
3 Best Stocks to Buy Now, 9/23/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 9/23/2025, According to Top Analysts
7d ago
ADVM
ATAI
Buy Rating for Adverum Biotechnologies: Promising Phase 3 Trial Progress and Financial Resilience
PremiumRatings
Buy Rating for Adverum Biotechnologies: Promising Phase 3 Trial Progress and Financial Resilience
7d ago
ADVM
Adverum Biotechnologies Completes Screening for Phase 3 Trial
PremiumCompany Announcements
Adverum Biotechnologies Completes Screening for Phase 3 Trial
8d ago
8K
ADVM
Adverum reports completion of screening for Phase 3 ARTEMIS trial
PremiumThe Fly
Adverum reports completion of screening for Phase 3 ARTEMIS trial
8d ago
ADVM
Private Markets: Anthropic raises $13B Series F at $183B post-money valuation
PremiumThe FlyPrivate Markets: Anthropic raises $13B Series F at $183B post-money valuation
25d ago
AI
GS
Promising Outlook for Adverum Biotechnologies’ Ixo-vec in Wet AMD Treatment: Buy Rating Affirmed
Premium
Ratings
Promising Outlook for Adverum Biotechnologies’ Ixo-vec in Wet AMD Treatment: Buy Rating Affirmed
2M ago
ADVM
Adverum Biotechnologies Faces Financial Challenges Amid Gene Therapy Development
Premium
Company Announcements
Adverum Biotechnologies Faces Financial Challenges Amid Gene Therapy Development
2M ago
ADVM
Adverum Biotechnologies reports Q2 EPS ($2.34), consensus ($2.28)
PremiumThe Fly
Adverum Biotechnologies reports Q2 EPS ($2.34), consensus ($2.28)
2M ago
ADVM
Adverum Biotechnologies sees cash runway into 4Q25
PremiumThe Fly
Adverum Biotechnologies sees cash runway into 4Q25
2M ago
ADVM
Adverum Biotechnologies price target lowered to $12 from $16 at Mizuho
PremiumThe Fly
Adverum Biotechnologies price target lowered to $12 from $16 at Mizuho
3M ago
ADVM
Adverum Biotechnologies Holds Annual Meeting with Key Votes
PremiumCompany Announcements
Adverum Biotechnologies Holds Annual Meeting with Key Votes
3M ago
8K
ADVM
Adverum Biotechnologies Reports Q1 2025 Financial Results
PremiumCompany AnnouncementsAdverum Biotechnologies Reports Q1 2025 Financial Results
5M ago
ADVM
Promising Outlook for Adverum Biotechnologies: Buy Rating on ixo-vec’s Advancements in Wet AMD Treatment
Premium
Ratings
Promising Outlook for Adverum Biotechnologies: Buy Rating on ixo-vec’s Advancements in Wet AMD Treatment
5M ago
ADVM
Adverum Biotechnologies price target lowered to $4 from $5 at RBC Capital
Premium
The Fly
Adverum Biotechnologies price target lowered to $4 from $5 at RBC Capital
5M ago
ADVM
Adverum Biotechnologies reports Q1 EPS ($2.25), consensus ($1.97)
PremiumThe Fly
Adverum Biotechnologies reports Q1 EPS ($2.25), consensus ($1.97)
5M ago
ADVM
Adverum Biotechnologies: Promising Gene Therapy Developments and Financial Stability Justify Buy Rating
PremiumRatings
Adverum Biotechnologies: Promising Gene Therapy Developments and Financial Stability Justify Buy Rating
6M ago
ADVM
Adverum Biotechnologies Reports 2024 Financial Results and Pipeline Progress
PremiumCompany Announcements
Adverum Biotechnologies Reports 2024 Financial Results and Pipeline Progress
6M ago
ADVM
Adverum Biotechnologies reports Q4 EPS ($1.96), consensus ($1.38)
PremiumThe Fly
Adverum Biotechnologies reports Q4 EPS ($1.96), consensus ($1.38)
6M ago
ADVM
Adverum Biotechnologies sees cash runway into 2H25
PremiumThe FlyAdverum Biotechnologies sees cash runway into 2H25
6M ago
ADVM
Adverum Biotechnologies announces anticipated milestones
Premium
The Fly
Adverum Biotechnologies announces anticipated milestones
6M ago
ADVM
Adverum Biotechnologies Delays Yearly Report Filing
Premium
Company Announcements
Adverum Biotechnologies Delays Yearly Report Filing
6M ago
ADVM

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >